Priscilla T Velentgas

Dr. Priscilla T Velentgas

orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2021 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Open access
PDF file
SCStephanie E. Chiuve
Stephanie E. Chiuve
RKRyan D. Kilpatrick
Ryan D. Kilpatrick
MHMark D. Hornstein
Mark D. Hornstein
NPNatalia Petruski‐Ivleva
Natalia Petruski‐Ivleva
LWLani R. Wegrzyn
Lani R. Wegrzyn
BBBrian T. Bateman
Brian T. Bateman
Background: Women with endometriosis are prescribed opioids for pain relief but may be vulnerable to chronic opioid use given their comorbidity profile.Methods: A cohort study was conducted in the Clinformatics™ DataMart database between 2006 and 2017 comparing women aged 18–50 years with endometriosis (N = 36 373) to those without (N = 2 172 936) in terms of risk of chronic opioid use, opioid dependence diagnosis, and opioid overdose. Chronic opioid use was defined as ≥120 days' supply dispensed or ≥10 fills of an opioid during any 365‐day interval. Among women with endometriosis, we evaluated factors associated with higher risk of chronic opioid use and quantified the risk of complications associated with the use of opioids.Results: Women with endometriosis were at greater risk for chronic opioid use (OR: 3.76; 95%CI: 3.57–3.96), dependence (OR: 2.73, 95%CI: 2.38–3.13) and overdose (OR: 4.34, 95%CI: 3.06–6.15) compared to women without. Chronic users displayed dose escalation and increase in days supplied over time, as well as co‐prescribing with benzodiazepines and sedatives. Approximately 34% of chronic users developed constipation, 20% experienced falls, and 8% reported dizziness. Among endometriosis patients, women in younger age groups, those with other comorbidities associated with pain symptoms, as well as those with depression or anxiety were at a higher risk of developing chronic opioid use.Conclusions: Women with endometriosis had a four times greater risk of chronic opioid use compared to women without. Multimorbidity among these patients was associated with the elevated risk of chronic opioid use and should be taken into account during treatment selection.

28 August 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
KFKristen Feemster
Kristen Feemster
WHWilliam Hausdorff
William Hausdorff
NBNatalie Banniettis
Natalie Banniettis
HPHeather Loryn Platt
Heather Loryn Platt
PVPriscilla T Velentgas
Priscilla T Velentgas
UBUlrike K Kirsten Buchwald
Ulrike K Kirsten Buchwald
Pneumococcal vaccines are a cornerstone for the prevention of pneumococcal diseases, reducing morbidity and mortality in children and adults worldwide. Pneumococcal vaccine composition is based on the polysaccharide capsule of Streptococcus pneumoniae, which is one of the most important identified contributors to the pathogen’s virulence. Similarities in the structural composition of polysaccharides included in licensed pneumococcal vaccines may result in cross-reactivity of immune response against closely related serotypes, including serotypes not included in the vaccine. Therefore, it is important to understand whether cross-reactive antibodies offer clinical protection against pneumococcal disease. This review explores available evidence of cross-reactivity and cross-protection associated with pneumococcal vaccines, the challenges associated with the assessment of cross-reactivity and cross-protection, and implications for vaccine design and development.

14 April 2025 in Vaccine
Verified
Journal Article
Closed access
RJR. Joshi
R. Joshi
HAH.T. Ayele
H.T. Ayele
KJKell Johnson
Kell Johnson
PVPriscilla T Velentgas
Priscilla T Velentgas
HPHeather Loryn Platt
Heather Loryn Platt
PSP. Saddier
P. Saddier

1 April 2010 in Journal of Clinical Epidemiology
Verified
Journal Article
Closed access
KMKristen M. Moore
Kristen M. Moore
ADApril Duddy
April Duddy
GLGrace M. Lee
Grace M. Lee
PVPriscilla T Velentgas
Priscilla T Velentgas
DBDale R. Burwen
Dale R. Burwen
JBJeffrey Brown
Jeffrey Brown

19 March 2025 in Infectious Diseases and Therapy
Verified
Journal Article
Open access
PDF file
KBKevin Bakker
Kevin Bakker
RORachel J. Oidtman
Rachel J. Oidtman
NBNatalie Banniettis
Natalie Banniettis
KFKristen Feemster
Kristen Feemster
PVPriscilla T Velentgas
Priscilla T Velentgas
JWJessica Weaver
Jessica Weaver
Introduction Pneumococcal conjugate vaccines (PCVs) have been increasing in valency to protect against a larger number of serotypes; however, the addition of serotypes has come at the cost of reduced immunogenicity, which may lead to breakthrough disease. Methods This study used a mathematical model to evaluate the impact of introducing routine vaccination with either PCV15 or PCV20 on breakthrough invasive pneumococcal disease (bIPD) incidence associated with PCV13 serotypes in infants aged 0–12 months in France. The model incorporated historical PCV introductions and calibrated age- and serotype-specific IPD data spanning 2000–2019. Serotype-specific vaccine effectiveness for PCV15 and PCV20 was predicted based on previously published analyses. The incidence of bIPD was evaluated across three serotype classes: PCV7 (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F), PCV13-nonPCV7-nonST3 (serotypes 1, 5, 6A, 7F, and 19A), and ST3 (serotype 3). Results were compared to IPD incidence in 2019. Results Twenty years following introduction into the childhood immunization program, the routine use of PCV15 in a 2 + 1 regimen led to fewer PCV13-nonPCV7-nonST3-associated bIPD cases in infants than the use of PCV20 in either a 2 + 1 or 3 + 1 regimen. PCV15 reduced bIPD incidence in all three serotype classes (– 28% to – 89%) in infants, with the largest impact on ST3. PCV20 in both regimens resulted in more bIPD cases from PCV7 serotypes (+ 65% to + 350%), while PCV13-nonPCV7-nonST3 and ST3 bIPD cases increased in a 2 + 1 regimen (+ 28% and + 6%, respectively) but decreased in a 3 + 1 regimen (– 23% and – 30%, respectively), in infants. Conclusions Implementation of PCV15 in a 2 + 1 regimen could reduce bIPD incidence due to all PCV13 serotypes in infants, whereas PCV20 in a 2 + 1 regimen may lead to substantial increases in bIPD cases from PCV13 serotypes in infants. PCV20 in a 3 + 1 regimen could potentially lead to a resurgence of bIPD from PCV7 serotypes in infants.

4 August 2025 in Vaccines
Verified
Journal Article
Open access
PDF file
KFKristen Feemster
Kristen Feemster
WHWilliam Hausdorff
William Hausdorff
NBNatalie Banniettis
Natalie Banniettis
HPHeather Loryn Platt
Heather Loryn Platt
PVPriscilla T Velentgas
Priscilla T Velentgas
UBUlrike K Kirsten Buchwald
Ulrike K Kirsten Buchwald
The authors would like to make the following corrections to this published paper